EW241115C92500
- 0.14
- 0.000.00%
Edwards Lifesciences Newsroom
Monday Market Mixed Before Crazy, Piovitol Week | Live Stock
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $81 From $80, Maintains Buy Rating
Weekly Buzz: Magnificent Mix of Market Reactions
November Starts with a Climb to end Tough Week | Wall Street Today
Friday Market Climbs on Amazon Earnings, Labor Numbers at Four-Year Low | Live Stock
Edwards Lifesciences Corporation (EW) Fell Due to Missed Earnings Expectations and Weak Guidance
TD Cowen Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Piper Sandler Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Thursday, Halloween Market Falls in Scary Reaction to Earnings | Wall Street Today
Halloween Market Falls, Scared of Meta and Microsoft CapEx | Live Stock
Market Flips and Falls as Meta and MSTR Fall After Earnings | Wall Street Today
Edwards Life Says Pivotal Study for Evoque Hit One-year Goal
Why Is Boston Scientific Stock Trading Lower On Wednesday?
Market Climbs, SMCI Auditors Allege Mischief on Mischief Night | Live Stock
Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
Express News | Triscend II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
Daiwa Downgrades Edwards Lifesciences to Neutral From Outperform, Price Target Is $72
Nasdaq Hits Record High While Wed Earnings Are Mixed | Wall Street Today